Creative Medical Technology (NASDAQ:CELZ) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings data on Friday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.16), FiscalAI reports.

Creative Medical Technology Stock Up 2.6%

NASDAQ:CELZ traded up $0.02 during trading hours on Friday, reaching $0.62. 106,318 shares of the company traded hands, compared to its average volume of 107,754. The business’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $1.54. Creative Medical Technology has a 1 year low of $0.59 and a 1 year high of $4.72.

Wall Street Analysts Forecast Growth

CELZ has been the subject of a number of recent research reports. Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Weiss Ratings cut Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Creative Medical Technology presently has a consensus rating of “Hold”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.

The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.